anti-cd19 ucar-nk cells
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2022 (NCT05570188)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05654038 | Phase 1/Phase 2 (Phase 2) | Dec 8, 2022 | People's Liberation Army of China |
| NCT05570188 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2022 | Kunming Hope of Health Hospital |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kunming Hope of Health Hospital | Academic/Hospital | 1 | 1 | 1 | 2022 |
| People's Liberation Army of China | Government | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1